Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
151823-14-2CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1LBGFKUUHOPIEMA-PEARBKPGSA-NSapacitabine is a nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML). It has a role as an antimetabolite, an antineoplastic agent, a prodrug and a DNA synthesis inhibitor. It is a secondary carboxamide, a nitrile and a nucleoside analogue. It is functionally related to a CNDAC and a hexadecanoic acid.
151823-14-2DTXSID90164887CHEMBL2105681CHEBI:145429Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sapacitabine appears to act through a dual mechanism. It interferes with DNA synthesis by causing single-strand DNA breaks and also induces arrest of cell cycle progression mainly at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite or a substance into which the drugs converts after ingestion by patients, have demonstrated potent anti-tumor activity in preclinical studies.
VerwendenSapacitabine, it is an orally available nucleoside analog prodrug of CNDAC that acts through a dual mechanism. It has potential use in chemotherapy.